Abnova (Taiwan) Corporation Logo

Abnova (Taiwan) Corporation

4133.TW

(2.0)
Stock Price

28,85 TWD

5.04% ROA

5.14% ROE

28.01x PER

Market Cap.

1.846.884.800,00 TWD

0.46% DER

2.36% Yield

18.08% NPM

Abnova (Taiwan) Corporation Stock Analysis

Abnova (Taiwan) Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Abnova (Taiwan) Corporation Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (1%), which means it has a small amount of debt compared to the ownership it holds

2 Dividend

Shareholders can rely on the company's remarkable dividend history, consistently paying dividends for the past five years, demonstrating a steadfast dedication to rewarding investors.

3 ROE

The stock's ROE falls within an average range (4.86%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (4.57%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 PBV

The stock's PBV ratio (1.53x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

6 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (853), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

7 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

9 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

10 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

11 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Abnova (Taiwan) Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Abnova (Taiwan) Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Abnova (Taiwan) Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Abnova (Taiwan) Corporation Revenue
Year Revenue Growth
2009 402.834.000
2010 475.072.000 15.21%
2011 472.569.000 -0.53%
2012 463.774.000 -1.9%
2013 463.699.000 -0.02%
2014 438.112.000 -5.84%
2015 451.367.000 2.94%
2016 439.826.000 -2.62%
2017 475.073.000 7.42%
2018 426.023.000 -11.51%
2019 414.158.000 -2.86%
2020 456.449.000 9.27%
2021 451.487.000 -1.1%
2022 411.756.000 -9.65%
2023 375.592.000 -9.63%
2023 382.052.000 1.69%
2024 367.112.000 -4.07%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Abnova (Taiwan) Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2009 27.950.000
2010 30.638.000 8.77%
2011 28.858.000 -6.17%
2012 38.561.000 25.16%
2013 40.667.000 5.18%
2014 42.744.000 4.86%
2015 48.858.000 12.51%
2016 48.548.000 -0.64%
2017 52.700.000 7.88%
2018 56.621.000 6.92%
2019 54.735.000 -3.45%
2020 50.957.000 -7.41%
2021 53.141.000 4.11%
2022 48.740.000 -9.03%
2023 36.272.000 -34.37%
2023 38.396.000 5.53%
2024 34.908.000 -9.99%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Abnova (Taiwan) Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2009 52.902.000
2010 59.278.000 10.76%
2011 60.184.000 1.51%
2012 64.960.000 7.35%
2013 60.579.000 -7.23%
2014 65.513.000 7.53%
2015 64.947.000 -0.87%
2016 62.597.000 -3.75%
2017 70.858.000 11.66%
2018 66.554.000 -6.47%
2019 58.203.000 -14.35%
2020 55.894.000 -4.13%
2021 59.365.000 5.85%
2022 47.216.000 -25.73%
2023 48.296.000 2.24%
2023 46.117.000 -4.72%
2024 51.568.000 10.57%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Abnova (Taiwan) Corporation EBITDA
Year EBITDA Growth
2009 162.888.000
2010 187.917.000 13.32%
2011 174.857.000 -7.47%
2012 134.790.000 -29.73%
2013 118.594.000 -13.66%
2014 101.195.000 -17.19%
2015 87.261.000 -15.97%
2016 84.312.000 -3.5%
2017 109.398.000 22.93%
2018 79.505.000 -37.6%
2019 75.408.000 -5.43%
2020 97.258.000 22.47%
2021 79.790.000 -21.89%
2022 130.299.000 38.76%
2023 94.624.000 -37.7%
2023 77.917.000 -21.44%
2024 73.108.000 -6.58%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Abnova (Taiwan) Corporation Gross Profit
Year Gross Profit Growth
2009 230.824.000
2010 281.667.000 18.05%
2011 268.539.000 -4.89%
2012 254.226.000 -5.63%
2013 236.188.000 -7.64%
2014 223.752.000 -5.56%
2015 213.705.000 -4.7%
2016 206.656.000 -3.41%
2017 228.868.000 9.71%
2018 185.380.000 -23.46%
2019 185.350.000 -0.02%
2020 213.501.000 13.19%
2021 197.339.000 -8.19%
2022 201.429.000 2.03%
2023 162.448.000 -24%
2023 173.915.000 6.59%
2024 152.828.000 -13.8%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Abnova (Taiwan) Corporation Net Profit
Year Net Profit Growth
2009 99.558.000
2010 149.045.000 33.2%
2011 119.865.000 -24.34%
2012 76.838.000 -56%
2013 72.896.000 -5.41%
2014 65.643.000 -11.05%
2015 44.911.000 -46.16%
2016 53.539.000 16.12%
2017 58.966.000 9.2%
2018 46.118.000 -27.86%
2019 3.263.000 -1313.36%
2020 36.526.000 91.07%
2021 28.369.000 -28.75%
2022 74.843.000 62.1%
2023 40.608.000 -84.31%
2023 43.678.000 7.03%
2024 73.180.000 40.31%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Abnova (Taiwan) Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2009 2
2010 2 50%
2011 2 -100%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 0 0%
2020 1 0%
2021 0 0%
2022 1 100%
2023 1 0%
2023 1 0%
2024 1 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Abnova (Taiwan) Corporation Free Cashflow
Year Free Cashflow Growth
2009 48.713.000
2010 96.672.000 49.61%
2011 104.381.000 7.39%
2012 35.762.000 -191.88%
2013 75.672.000 52.74%
2014 74.517.000 -1.55%
2015 -94.864.000 178.55%
2016 -6.342.000 -1395.81%
2017 -20.449.000 68.99%
2018 4.847.000 521.89%
2019 61.217.000 92.08%
2020 97.564.000 37.25%
2021 92.041.000 -6%
2022 118.508.000 22.33%
2023 47.333.000 -150.37%
2023 173.000 -27260.12%
2024 40.135.000 99.57%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Abnova (Taiwan) Corporation Operating Cashflow
Year Operating Cashflow Growth
2009 63.721.000
2010 114.400.000 44.3%
2011 134.225.000 14.77%
2012 76.021.000 -76.56%
2013 109.778.000 30.75%
2014 94.180.000 -16.56%
2015 73.428.000 -28.26%
2016 71.936.000 -2.07%
2017 67.529.000 -6.53%
2018 89.168.000 24.27%
2019 74.513.000 -19.67%
2020 105.300.000 29.24%
2021 92.875.000 -13.38%
2022 132.369.000 29.84%
2023 76.219.000 -73.67%
2023 4.886.000 -1459.95%
2024 40.854.000 88.04%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Abnova (Taiwan) Corporation Capital Expenditure
Year Capital Expenditure Growth
2009 15.008.000
2010 17.728.000 15.34%
2011 29.844.000 40.6%
2012 40.259.000 25.87%
2013 34.106.000 -18.04%
2014 19.663.000 -73.45%
2015 168.292.000 88.32%
2016 78.278.000 -114.99%
2017 87.978.000 11.03%
2018 84.321.000 -4.34%
2019 13.296.000 -534.18%
2020 7.736.000 -71.87%
2021 834.000 -827.58%
2022 13.861.000 93.98%
2023 28.886.000 52.01%
2023 4.713.000 -512.9%
2024 719.000 -555.49%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Abnova (Taiwan) Corporation Equity
Year Equity Growth
2009 1.210.173.000
2010 1.269.898.000 4.7%
2011 1.270.668.000 0.06%
2012 1.228.937.000 -3.4%
2013 1.229.757.000 0.07%
2014 1.229.724.000 -0%
2015 1.166.627.000 -5.41%
2016 1.176.217.000 0.82%
2017 1.224.730.000 3.96%
2018 1.227.232.000 0.2%
2019 1.192.403.000 -2.92%
2020 1.211.094.000 1.54%
2021 1.211.756.000 0.05%
2022 1.291.994.000 6.21%
2023 1.280.505.000 -0.9%
2023 1.286.319.000 0.45%
2024 1.292.210.000 0.46%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Abnova (Taiwan) Corporation Assets
Year Assets Growth
2009 1.305.517.000
2010 1.334.137.000 2.15%
2011 1.355.176.000 1.55%
2012 1.292.059.000 -4.88%
2013 1.285.178.000 -0.54%
2014 1.307.877.000 1.74%
2015 1.248.979.000 -4.72%
2016 1.248.276.000 -0.06%
2017 1.303.783.000 4.26%
2018 1.294.998.000 -0.68%
2019 1.263.989.000 -2.45%
2020 1.294.584.000 2.36%
2021 1.283.049.000 -0.9%
2022 1.374.829.000 6.68%
2023 1.366.551.000 -0.61%
2023 1.355.743.000 -0.8%
2024 1.374.579.000 1.37%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Abnova (Taiwan) Corporation Liabilities
Year Liabilities Growth
2009 95.344.000
2010 64.239.000 -48.42%
2011 84.508.000 23.98%
2012 63.122.000 -33.88%
2013 55.421.000 -13.9%
2014 78.153.000 29.09%
2015 82.352.000 5.1%
2016 72.059.000 -14.28%
2017 79.053.000 8.85%
2018 67.766.000 -16.66%
2019 71.586.000 5.34%
2020 83.490.000 14.26%
2021 71.293.000 -17.11%
2022 82.835.000 13.93%
2023 86.046.000 3.73%
2023 69.424.000 -23.94%
2024 82.369.000 15.72%

Abnova (Taiwan) Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
6.02
Net Income per Share
1.09
Price to Earning Ratio
28.01x
Price To Sales Ratio
5.06x
POCF Ratio
35.4
PFCF Ratio
51.88
Price to Book Ratio
1.43
EV to Sales
3.83
EV Over EBITDA
16.27
EV to Operating CashFlow
26.78
EV to FreeCashFlow
39.25
Earnings Yield
0.04
FreeCashFlow Yield
0.02
Market Cap
1,85 Bil.
Enterprise Value
1,40 Bil.
Graham Number
22.87
Graham NetNet
10.2

Income Statement Metrics

Net Income per Share
1.09
Income Quality
0.83
ROE
0.05
Return On Assets
0.05
Return On Capital Employed
0.05
Net Income per EBT
1
EBT Per Ebit
1.02
Ebit per Revenue
0.18
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.13
Research & Developement to Revenue
0.1
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.45
Operating Profit Margin
0.18
Pretax Profit Margin
0.18
Net Profit Margin
0.18

Dividends

Dividend Yield
0.02
Dividend Yield %
2.36
Payout Ratio
1.4
Dividend Per Share
0.72

Operating Metrics

Operating Cashflow per Share
0.86
Free CashFlow per Share
0.59
Capex to Operating CashFlow
0.32
Capex to Revenue
0.05
Capex to Depreciation
0.54
Return on Invested Capital
0.05
Return on Tangible Assets
0.05
Days Sales Outstanding
42.6
Days Payables Outstanding
33.01
Days of Inventory on Hand
774.17
Receivables Turnover
8.57
Payables Turnover
11.06
Inventory Turnover
0.47
Capex per Share
0.27

Balance Sheet

Cash per Share
7,53
Book Value per Share
21,34
Tangible Book Value per Share
20.27
Shareholders Equity per Share
21.34
Interest Debt per Share
0.1
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-5.23
Current Ratio
12.5
Tangible Asset Value
1,23 Bil.
Net Current Asset Value
0,87 Bil.
Invested Capital
1198140000
Working Capital
0,87 Bil.
Intangibles to Total Assets
0.05
Average Receivables
0,04 Bil.
Average Payables
0,02 Bil.
Average Inventory
419591000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Abnova (Taiwan) Corporation Dividends
Year Dividends Growth
2010 3
2011 2 -100%
2012 2 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 0 0%
2017 0 0%
2018 1 0%
2019 1 0%
2020 0 0%
2021 1 0%
2022 0 0%
2023 1 0%
2024 1 0%

Abnova (Taiwan) Corporation Profile

About Abnova (Taiwan) Corporation

Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2, DNA and RNA, proteins/peptides, DNAxPab, beads/dyes, lysates/slides, antibody pairs/kits, antibody and tissue arrays, in situ hybridization products, systems and automations, GMP and analyte specific reagents, and in vitro diagnostics. It also provides MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company offers integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production; and assay development services. Abnova (Taiwan) Corporation is headquartered in Taipei, Taiwan.

CEO
Yi Huang Huang
Employee
110
Address
No. 108, Jhouzih Street
Taipei, 114

Abnova (Taiwan) Corporation Executives & BODs

Abnova (Taiwan) Corporation Executives & BODs
# Name Age
1 Yi Huang Huang
Deputy General Manager
70

Abnova (Taiwan) Corporation Competitors